Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Anchor Investment Management LLC

Anchor Investment Management LLC decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,148 shares of the medical equipment provider’s stock after selling 610 shares during the quarter. Anchor Investment Management LLC’s holdings in Zimmer Biomet were worth $1,311,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Dunhill Financial LLC boosted its position in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of Zimmer Biomet in the 3rd quarter worth $28,000. Bangor Savings Bank purchased a new position in Zimmer Biomet in the 3rd quarter worth $31,000. Family Firm Inc. purchased a new position in Zimmer Biomet in the 2nd quarter worth $33,000. Finally, Brooklyn Investment Group purchased a new position in Zimmer Biomet in the 3rd quarter worth $35,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 0.1 %

ZBH stock opened at $106.84 on Friday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The stock has a market cap of $21.27 billion, a price-to-earnings ratio of 20.31, a PEG ratio of 1.96 and a beta of 1.02. The business’s 50-day moving average is $107.59 and its 200 day moving average is $108.83.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. During the same period in the previous year, the firm posted $1.65 EPS. Zimmer Biomet’s revenue was up 4.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their target price on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research note on Monday, September 16th. Raymond James reduced their target price on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Truist Financial raised their target price on Zimmer Biomet from $112.00 to $117.00 and gave the stock a “hold” rating in a research note on Friday, November 1st. Wells Fargo & Company raised their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Finally, Wolfe Research assumed coverage on Zimmer Biomet in a research note on Tuesday, September 10th. They set a “peer perform” rating for the company. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $122.83.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.